

Steven M Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2491421/publications.pdf>

Version: 2024-02-01

65
papers

1,504
citations

566801

15
h-index

344852

36
g-index

66
all docs

66
docs citations

66
times ranked

2176
citing authors

#	ARTICLE	IF	CITATIONS
1	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 154-159.	2.2	5
2	Evaluation of a Beta-blocker "Edema" Loop Diuretic Prescribing Cascade: A Prescription Sequence Symmetry Analysis. <i>American Journal of Hypertension</i> , 2022, , .	1.0	5
3	Acetaminophen-Induced Hypertension: Where Have All the "Safe" Analgesics Gone?. <i>Circulation</i> , 2022, 145, 424-426.	1.6	1
4	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. <i>American Heart Journal Plus</i> , 2022, 13, 100112.	0.3	3
5	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. <i>Diabetes Care</i> , 2022, 45, 1007-1012.	4.3	4
6	Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression. <i>Pharmacotherapy</i> , 2022, , .	1.2	3
7	Risk of Obstructive Sleep Apnea in Adults with Resistant Hypertension. , 2022, 1, 26-32.		1
8	Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 851-860.	2.2	5
9	U.S. trends in prescription nonsteroidal anti-inflammatory drug use among patients with cardiovascular disease, 1988-2016. <i>Pharmacotherapy</i> , 2021, 41, 247-256.	1.2	4
10	Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. <i>Clinical and Translational Science</i> , 2021, 14, 617-624.	1.5	1
11	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. <i>PLoS ONE</i> , 2021, 16, e0248080.	1.1	17
12	Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1381-1385.	0.9	0
13	Newer drug treatments for type 2 diabetes. <i>BMJ, The</i> , 2021, 373, n1171.	3.0	4
14	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. <i>Pharmacotherapy</i> , 2021, 41, 710-721.	1.2	1
15	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. <i>Metabolites</i> , 2021, 11, 645.	1.3	7
16	Potential of Minocycline for Treatment of Resistant Hypertension. <i>American Journal of Cardiology</i> , 2021, 156, 147-149.	0.7	5
17	Comparative Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Response to a Physical Activity Intervention in Older Adults: Results From the Lifestyle Interventions and Independence for Elders Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1010-1016.	1.7	10
18	Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The International Verapamil SR-Trandolapril Study (INVEST). <i>Journal of Women's Health</i> , 2020, 29, 158-166.	1.5	1

#	ARTICLE	IF	CITATIONS
19	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 705-710.	2.2	3
20	Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. <i>Clinical Therapeutics</i> , 2020, 42, e161-e176.	1.1	2
21	Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1987-1992.	1.0	8
22	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVESTA†. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100052.	2.2	1
23	Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States. <i>American Journal of Hypertension</i> , 2020, 33, 999-1002.	1.0	3
24	Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008–2017. <i>International Journal of Cardiology: Hypertension</i> , 2020, 6, 100033.	2.2	9
25	Redefining Resistant Hypertension. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005979.	0.9	2
26	Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 188-195.	0.5	13
27	Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace. <i>Journal of Clinical Hypertension</i> , 2020, 22, 6-15.	1.0	10
28	Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison. <i>JMIR Medical Informatics</i> , 2020, 8, e14777.	1.3	12
29	Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-36.	2.2	58
30	<scp>ARB</scp> Superiority Over <scp>ACE</scp> Inhibitors in Coronary Heart Disease: An Alternative Viewpoint. <i>Pharmacotherapy</i> , 2019, 39, 204-206.	1.2	1
31	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e624-e625.	0.6	0
32	Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. <i>Journal of Clinical Hypertension</i> , 2019, 21, 825-834.	1.0	15
33	Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention. <i>Annals of Pharmacotherapy</i> , 2019, 53, 933-939.	0.9	17
34	Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. <i>American Journal of Medicine</i> , 2019, 132, 172-174.	0.6	14
35	Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients. <i>Annals of Pharmacotherapy</i> , 2018, 52, 554-561.	0.9	10
36	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 620-624.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. <i>Journal of Hypertension</i> , 2018, 36, 419-427.	0.3	5
38	OneFlorida Clinical Research Consortium: Linking a Clinical and Translational Science Institute With a Community-Based Distributive Medical Education Model. <i>Academic Medicine</i> , 2018, 93, 451-455.	0.8	77
39	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018, 72, e53-e90.	1.3	629
40	Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. <i>Preventing Chronic Disease</i> , 2018, 15, E27.	1.7	15
41	Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension. <i>American Journal of Hypertension</i> , 2018, 31, 1324-1331.	1.0	16
42	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2018, 17, 102.	2.7	17
43	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. <i>American Journal of Medicine</i> , 2018, 131, 1463-1472.e7.	0.6	16
44	Evaluation of SAME-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1085-1090.	0.9	0
45	Efficacy and safety of twiceâ€vs onceâ€daily dosing of lisinopril for hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 868-873.	1.0	7
46	Resistant Hypertension: Mechanisms and Treatment. <i>Current Hypertension Reports</i> , 2017, 19, 56.	1.5	27
47	Resistant Hypertension and Susceptible Outcomes: Exploring the Benefits of Aggressive Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2016, 18, 40-42.	1.0	3
48	Patient satisfaction with extended-interval warfarin monitoring. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 486-493.	1.0	8
49	Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014. <i>Hypertension</i> , 2016, 68, 1349-1354.	1.3	38
50	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. <i>Journal of Women's Health</i> , 2016, 25, 996-1003.	1.5	14
51	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 307-317.	2.3	28
52	Quality of Life in Treatment-Resistant Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 61.	1.5	12
53	Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin. <i>Cardiovascular Therapeutics</i> , 2015, 33, 98-103.	1.1	9
54	Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension. <i>Evidence-Based Medicine</i> , 2015, 20, 58-58.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Physician Acceptance of a Physician-Pharmacist Collaborative Treatment Model for Hypertension Management in Primary Care. <i>Journal of Clinical Hypertension</i> , 2015, 17, 686-691.	1.0	8
56	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study. <i>Journal of the American Heart Association</i> , 2014, 3, e000660.	1.6	57
57	Baseline predictors of central aortic blood pressure: A PEAR substudy. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 152-158.	2.3	10
58	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 635-643.	0.3	88
59	Reply to "Resistant hypertension revisited." <i>Journal of Hypertension</i> , 2014, 32, 1547.	0.3	1
60	Epidemiology, Prognosis, and Treatment of Resistant Hypertension. <i>Pharmacotherapy</i> , 2013, 33, 1071-1086.	1.2	13
61	Phentermine/Topiramate for the Treatment of Obesity. <i>Annals of Pharmacotherapy</i> , 2013, 47, 340-349.	0.9	71
62	Cost-Effectiveness of Renin-Guided Treatment of Hypertension. <i>American Journal of Hypertension</i> , 2013, 26, 1303-1310.	1.0	14
63	Antivirals for Influenza. <i>Paediatric Drugs</i> , 2010, 12, 285-299.	1.3	12
64	Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. <i>Pharmacotherapy</i> , 2009, 29, 1157-1165.	1.2	30
65	Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 813-822.	1.5	19